Free Trial

HEALTHCARE: Eli Lilly beating Novo Nordisk

HEALTHCARE

NBC Reports: "According to Lilly’s trial results, patients who got weekly injections of Zepbound lost an average 20.2% of their body weight, or 50.3 pounds, after 72 weeks, compared with an average of 13.7% body weight, or 33.1 pounds, for those who got Wegovy.

That means, Lilly says, Zepbound provides 47% more weight loss than Wegovy."

55 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

NBC Reports: "According to Lilly’s trial results, patients who got weekly injections of Zepbound lost an average 20.2% of their body weight, or 50.3 pounds, after 72 weeks, compared with an average of 13.7% body weight, or 33.1 pounds, for those who got Wegovy.

That means, Lilly says, Zepbound provides 47% more weight loss than Wegovy."